Objectives

After participating in this educational activity, attendees should be able to:

1|Discuss the spectrum of neurological toxicity from active cancer treatment. 
2|Discuss diagnostic work-up and management strategies for common toxicities.
3|Discuss new evolving manifestations of immunological adverse events seen with newer T-cell-directed cancer therapies.

Presenter(s):

Dr. Sasmit Sarangi, M.B.B.S., MD 
Department of Neurology

NameRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?

Dr. Sasmit Sarangi, M.B.B.S MD 		SpeakerFore Biotherapuetics research support to institution only for clinical trial - Site PI for trial Yes/Tocilizumab and Anakinra
Session date: 
11/05/2025 - 9:00am to 10:00am EST
Location: 
Zoom
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category 1 CME credit
    Baystate Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PA’s should only claim credit commensurate with the extent of their participation.
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC Contact Hours
  • 1.00 IPCE Credit Hour(s)
Please login or register to take this course.